170 related articles for article (PubMed ID: 38173721)
1. Light-enhanced VEGF
Longva AS; Berg K; Weyergang A
Front Immunol; 2023; 14():1278000. PubMed ID: 38173721
[TBL] [Abstract][Full Text] [Related]
2. Light-enhanced VEGF
Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
[TBL] [Abstract][Full Text] [Related]
3. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Light-enhanced VEGF
Longva AS; Berg K; Weyergang A
Front Immunol; 2023; 14():1359973. PubMed ID: 38264651
[TBL] [Abstract][Full Text] [Related]
5. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
Mohamedali KA; Kedar D; Sweeney P; Kamat A; Davis DW; Eve BY; Huang S; Thorpe PE; Dinney CP; Rosenblum MG
Neoplasia; 2005 Oct; 7(10):912-20. PubMed ID: 16242074
[TBL] [Abstract][Full Text] [Related]
6. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
[TBL] [Abstract][Full Text] [Related]
7. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
[TBL] [Abstract][Full Text] [Related]
8. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
[TBL] [Abstract][Full Text] [Related]
9. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
[TBL] [Abstract][Full Text] [Related]
10. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
[TBL] [Abstract][Full Text] [Related]
11. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin).
Tanaka M; Kataoka H; Yano S; Sawada T; Akashi H; Inoue M; Suzuki S; Inagaki Y; Hayashi N; Nishie H; Shimura T; Mizoshita T; Mori Y; Kubota E; Tanida S; Takahashi S; Joh T
Oncotarget; 2016 Jul; 7(30):47242-47251. PubMed ID: 27363018
[TBL] [Abstract][Full Text] [Related]
14. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
16. M1-derived extracellular vesicles enhance photodynamic therapy and promote immunological memory in preclinical models of colon cancer.
Huis In 't Veld RV; Lara P; Jager MJ; Koning RI; Ossendorp F; Cruz LJ
J Nanobiotechnology; 2022 Jun; 20(1):252. PubMed ID: 35658868
[TBL] [Abstract][Full Text] [Related]
17. Translocator protein-targeted photodynamic therapy for direct and abscopal immunogenic cell death in colorectal cancer.
Xie Q; Li Z; Liu Y; Zhang D; Su M; Niitsu H; Lu Y; Coffey RJ; Bai M
Acta Biomater; 2021 Oct; 134():716-729. PubMed ID: 34329783
[TBL] [Abstract][Full Text] [Related]
18. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma.
Sanovic R; Verwanger T; Hartl A; Krammer B
Photodiagnosis Photodyn Ther; 2011 Dec; 8(4):291-6. PubMed ID: 22122915
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
